Magnesium Deficiency Causes a Reversible, Metabolic, Diastolic Cardiomyopathy

J Am Heart Assoc. 2021 Jun 15;10(12):e020205. doi: 10.1161/JAHA.120.020205. Epub 2021 Jun 5.

Abstract

Background Dietary Mg intake is associated with a decreased risk of developing heart failure, whereas low circulating Mg level is associated with increased cardiovascular mortality. We investigated whether Mg deficiency alone could cause cardiomyopathy. Methods and Results C57BL/6J mice were fed with a low Mg (low-Mg, 15-30 mg/kg Mg) or a normal Mg (nl-Mg, 600 mg/kg Mg) diet for 6 weeks. To test reversibility, half of the low-Mg mice were fed then with nl-Mg diet for another 6 weeks. Low-Mg diet significantly decreased mouse serum Mg (0.38±0.03 versus 1.14±0.03 mmol/L for nl-Mg; P<0.0001) with a reciprocal increase in serum Ca, K, and Na. Low-Mg mice exhibited impaired cardiac relaxation (ratio between mitral peak early filling velocity E and longitudinal tissue velocity of the mitral anterior annulus e, 21.1±1.1 versus 15.4±0.4 for nl-Mg; P=0.011). Cellular ATP was decreased significantly in low-Mg hearts. The changes were accompanied by mitochondrial dysfunction with mitochondrial reactive oxygen species overproduction and membrane depolarization. cMyBPC (cardiac myosin-binding protein C) was S-glutathionylated in low-Mg mouse hearts. All these changes were normalized with Mg repletion. In vivo (2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride treatment during low-Mg diet improved cardiac relaxation, increased ATP levels, and reduced S-glutathionylated cMyBPC. Conclusions Mg deficiency caused a reversible diastolic cardiomyopathy associated with mitochondrial dysfunction and oxidative modification of cMyBPC. In deficiency states, Mg supplementation may represent a novel treatment for diastolic heart failure.

Keywords: Ca handling; diastolic dysfunction; hypomagnesemia; mitochondrial dysfunction.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Antioxidants / pharmacology
  • Calcium Signaling
  • Cardiomyopathies / drug therapy
  • Cardiomyopathies / etiology*
  • Cardiomyopathies / metabolism
  • Cardiomyopathies / physiopathology
  • Carrier Proteins / metabolism
  • Diastole
  • Disease Models, Animal
  • Magnesium Deficiency / complications*
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / metabolism*
  • Myocardial Contraction* / drug effects
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Organophosphorus Compounds / pharmacology
  • Piperidines / pharmacology
  • Reactive Oxygen Species / metabolism
  • Ventricular Function, Left* / drug effects

Substances

  • Antioxidants
  • Carrier Proteins
  • MitoTEMPO
  • Organophosphorus Compounds
  • Piperidines
  • Reactive Oxygen Species
  • myosin-binding protein C
  • Adenosine Triphosphate